ArticleTranslational pediatrics2026
Rare 19q13.42 duplication encompassing
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Duplications at the 19q13.42 region are rare, and the relationship between 19q13.42 duplications and neurodevelopmental phenotypes remains poorly characterized due to the paucity of cases with well-documented clinical features. Methods: Cases with 19q13.42 duplications were reviewed from a cohort of over seventy-five thousand pediatric patients. These patients, suspected of having genetic diseases, underwent next-generation sequencing (NGS) at two collaborating medical centers between 2016 and December 2024. Cases were identified and subjected to further phenotypic and genomic analysis. The reported cases of 19q13.42 duplications were also searched in public resources. Results: Twenty patients, including 10 cases from our study and 10 cases from public resources with 19q13.42 duplication were enrolled. The duplication breakpoints detected by NGS in internal cases were nonrecurrent and the duplication sizes ranged from 76.864 to 724.194 Kb, which were verified by quantitative real-time polymerase chain reaction (qPCR). Neurodevelopmental disorders (NDDs) were the primary clinical phenotype, present in 94.1% (16/17) of patients. All 16 cases harbored duplications involving Conclusions: We observed recurrent neurodevelopmental features in a subset of reported 19q13.42 duplications and propose
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.